Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 166,100 shares, a growth of 2,002.5% from the January 31st total of 7,900 shares. Based on an average trading volume of 175,600 shares, the short-interest ratio is currently 0.9 days. Approximately 0.5% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Kamada Trading Down 2.7 %

NASDAQ KMDA opened at $6.91 on Friday. Kamada has a 12 month low of $4.74 and a 12 month high of $9.15. The stock’s fifty day moving average price is $7.01 and its 200-day moving average price is $6.10. The stock has a market cap of $397.19 million, a P/E ratio of 24.68, a P/E/G ratio of 0.97 and a beta of 0.99.

Institutional Trading of Kamada

Several institutional investors have recently bought and sold shares of KMDA. NewEdge Advisors LLC raised its holdings in Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after buying an additional 8,260 shares during the last quarter. Aristides Capital LLC increased its position in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Kamada in the 4th quarter worth about $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Kamada during the third quarter valued at approximately $77,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.